Home LiteratureArticle Details
PMID: 20202603 Published · ppublish English Letter Comment

Doubling back on centromere 17 in early breast cancer.

The Lancet. Oncology ·Vol. 11 ·No. 3 ·2010-03-00 ·Pages 216-7

Bedard PL, Desmedt C

Abstract

暂无摘要

MeSH Terms
Antibiotics, Antineoplastic/administration & dosage,pharmacology Antigens, Neoplasm/genetics Biomarkers, Pharmacological Breast Neoplasms/drug therapy Centromere DNA Topoisomerases, Type II/genetics DNA-Binding Proteins/genetics Epirubicin/administration & dosage,pharmacology Female Gene Amplification Genes, erbB-2/genetics Humans
Chemicals
Antibiotics, Antineoplastic Antigens, Neoplasm Biomarkers, Pharmacological DNA-Binding Proteins Epirubicin DNA Topoisomerases, Type II
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Bedard Philippe L
Desmedt Christine
Article Info
Journal
The Lancet. Oncology
Abbr.
Lancet Oncol
ISSN
1474-5488
DOI
10.1016/S1470-2045(10)70020-6
Published
2010-03-00
Pages
216-7
Language
English
Region
England
NLM ID
100957246
Subset
IM
Corrections
CommentOn
PMID: 20079691
External Links
PubMed source DOI: 10.1016/S1470-2045(10)70020-6 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2